Ahmad Mustafa Shiri,Tao Zhang,Tanja Bedke,Dimitra E Zazara,Lilan Zhao,Jöran Lücke,Morsal Sabihi,Antonella Fazio,Siwen Zhang,Daniele V F Tauriello,Eduard Batlle,Babett Steglich,Jan Kempski,Theodora Agalioti,Mikołaj Nawrocki,Yang Xu,Kristoffer Riecken,Imke Liebold,Leonie Brockmann,Leonie Konczalla,Lidia Bosurgi,Baris Mercanoglu,Philipp Seeger,Natalie Küsters,Panagis M Lykoudis,Asmus Heumann,Petra C Arck,Boris Fehse,Philipp Busch,Rainer Grotelüschen,Oliver Mann,Jakob R Izbicki,Thilo Hackert,Richard A Flavell,Nicola Gagliani,Anastasios D Giannou,Samuel Huber,Dimitra E. Zazara,Daniele V.F. Tauriello,Panagis M. Lykoudis,Petra C. Arck,Jakob R. Izbicki,Richard A. Flavell,Anastasios D. Giannou

Abstract:Background & Aims The liver is one of the organs most commonly affected by metastasis. The presence of liver metastasis is reported to be responsible for an immunosuppressive microenvironment and diminished immunotherapy efficacy. Here, we aimed to investigate the role of IL-10 in liver metastasis formation and decipher its therapeutic potential in affecting immunotherapy effectiveness. Methods To induce spontaneous or forced liver metastasis in mice, murine cancer cells (MC38) or colon tumor organoids were injected into the cecum or the spleen, respectively. Mice with complete and cell-type specific deletion of IL-10- and IL-10Ra were used to identify the source and the target of IL-10 during metastasis formation. Programmed death ligand 1 (PD-L1)-deficient mice were used to test the role of this checkpoint. Flow cytometry was applied to characterize the regulation of IL-10 on PD-L1. Results We found that Il10 -deficient mice and mice treated with IL-10Ra antibodies were protected against liver metastasis formation. Furthermore, by using IL-10 reporter mice, we demonstrated that Foxp3+ regulatory T cells (Tregs) were the major cellular source of IL-10 in liver metastatic sites. Accordingly, deletion of IL-10 in Tregs, but not in myeloid cells, led to reduced liver metastasis. Mechanistically, IL-10 acted on Tregs in an autocrine manner, thereby further amplifying IL-10 production. Furthermore, IL-10 acted on myeloid cells, i.e., monocytes, and induced the upregulation of the immune checkpoint protein PD-L1. Finally, the PD-L1/PD-1 axis attenuated CD8-dependent cytotoxicity against metastatic lesions. Conclusions Treg-derived IL-10 upregulates PD-L1 expression in monocytes, which in turn reduces CD8+ T-cell infiltration and related antitumor immunity in the context of colorectal cancer (CRC)-derived liver metastasis. These findings provide the basis for future monitoring and targeting of IL-10 in CRC-derived liver metastasis. Impact and implications Liver metastasis diminishes the effectiveness of immunotherapy and increases the mortality rate in CRC patients. We investigate the role of IL-10 in liver metastasis formation and decipher its therapeutic potential in affecting immunotherapy effectiveness. Our data identify IL-10 as a pro-metastatic factor in liver metastasis formation and characterize this cytokine as a regulator of PD-L1. This provides the basis for future monitoring and targeting of IL-10 in CRC-derived liver metastasis.

Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy

Inhibition of MC38 colon cancer growth by multicomponent chemoimmunotherapy with anti-IL-10R antibodies, HES-MTX nanoconjugate, depends on application of IL-12, IL-15 or IL-18 secreting dendritic cell vaccines

Intratumoral Injection of Interferon Gamma Promotes the Efficacy of Anti-Pd1 Treatment in Colorectal Cancer

Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Synergistic effect of radiotherapy and dendritic-cell-based immunotherapy via miR-15b-5p regulation in a colon carcinoma mouse model

Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

Combinational delivery of TLR4 and TLR7/8 agonist enhanced the therapeutic efficacy of immune checkpoint inhibitors to colon tumor

Enhanced gut barrier integrity sensitizes colon cancer to immune therapy

IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction

Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands

Interleukin 21 treatment in a murine model as a novel potential cytokine immunotherapy for colon cancer

Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.

In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2

Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer

Modulating the Tumor Microenvironment Via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.

Continuous Release of Interleukin 12 from Microencapsulated Engineered Cells for Colon Cancer Therapy

Powerful Anticolon Tumor Effect of Targeted Gene Immunotherapy Using Folate-Modified Nanoparticle Delivery of CCL19 To Activate the Immune System

Induction of therapeutic immunity and cancer eradication through biofunctionalized liposome-like nanovesicles derived from irradiated-cancer cells

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism